Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib plus S-1 with concurrent radiotherapy for unresectable pancreatic cancer
ChiCTR2400095015Phase 2Not yet recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and tegafur in pancreatic adenocarcinoma (PDAC), sponsored by Changzhou First People's Hospital. Primary endpoint: Objective response rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
fluzoparibtegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400095015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400095015.